Illumina Acquires SomaLogic to Boost Proteomics

An announcement from Illumina ( (ILMN) ) is now available.

On June 22, 2025, Illumina entered into a definitive agreement to acquire SomaLogic and other assets from Standard BioTools for $350 million in cash, with additional performance-based milestones and royalties. This acquisition aims to enhance Illumina’s presence in the expanding proteomics market and advance its multiomics strategy, building on a co-development partnership with SomaLogic since 2021. The transaction is expected to close in the first half of 2026, subject to regulatory approvals and customary conditions, and is anticipated to be profitable by 2027.

The most recent analyst rating on (ILMN) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.

Spark’s Take on ILMN Stock

According to Spark, TipRanks’ AI Analyst, ILMN is a Neutral.

Illumina’s overall stock score reflects significant financial performance challenges, with persistent losses and declining revenues weighing heavily. However, the technical analysis shows positive momentum, providing some optimism. The valuation remains weak due to a negative P/E ratio and no dividend yield. The earnings call highlighted both opportunities and substantial risks, particularly in the Greater China region and due to tariff impacts.

To see Spark’s full report on ILMN stock, click here.

More about Illumina

Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health by unlocking the power of the genome. The company serves customers in research, clinical, and applied markets with applications in life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Average Trading Volume: 2,234,767

Technical Sentiment Signal: Sell

Current Market Cap: $14.32B

See more data about ILMN stock on TipRanks’ Stock Analysis page.